Prevalence and Clinicopathologic features of different HER2 level in Chinese breast cancer patients - HER2 PATH

Study identifier:D9673R00011

ClinicalTrials.gov identifier:NCT05203458

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

HER2 Retrospective Epidemiology Study Prevalence and Clinicopathologic features of different HER2 level in Chinese breast cancer patients (HER2 PATH)

Medical condition

breast cancer, HER2

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

3136

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 24 Feb 2022
Primary Completion Date: 05 Jul 2023
Study Completion Date: 05 Jul 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria